Johnson & Johnson Innovation – JJDC helped the eye drop developer close a series A round that will fund development of lead asset Brimochol.
Visus Therapeutics, the US-based developer of a treatment for near vision loss, completed a $36m series A round yesterday featuring medical product group Johnson & Johnson.
The corporate participated through investment vehicle Johnson & Johnson Innovation – JJDC, investing together with hedge fund RTW Investments and multi-family office Wille.
Founded in 2019, Visus is developing an eye drop called Brimochol to correct for the loss of near vision associated with a condition known as presbyopia. The funding will be used to advance…
